Elucidating the Mechanisms of Hugan Buzure Granule in the Treatment of Liver Fibrosis via Network Pharmacology

Figure 6

The molecular docking of the compound target. (a) EGFR and luteolin-7-o-glucoside. (b) MAPK and sesamin. (c) CASP3 and luteolin-7-o-glucoside. (d) IL6 and luteolin-7-o-glucoside. (e) VEGF and delphinidin.

(a)

(b)

(c)

(d)

(e)